Yoshiyuki Miyazawa

Assistant Professor

Gunma University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2026

Year:

2026

Introduction Acquired factor V (FV) deficiency is a rare bleeding disorder requiring careful management, especially in hemodialysis (HD) patients who regularly receive anticoagulants. We present a case of recurrent acquired FV deficiency in a dialysis patient. Case Presentation A 76‐year‐old man on HD with a history of acquired FV deficiency developed third‐degree burns and persistent bleeding. Lab tests confirmed the recurrence of the deficiency. Initial treatments with rituximab and cyclophosphamide were ineffective. When prednisolone was rechallenged, the activity of coagulation FV was rapidly improved, and coagulation function was confirmed to have returned to normal. HD was managed without anticoagulants during critical periods. No major bleeding events were observed during HD. Conclusion This case underscores the complexities of managing acquired FV deficiency in patients on HD. It highlights the importance of individualized anticoagulation strategies and close monitoring of coagulation profiles to prevent bleeding complications and ensure the safety of HD.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Objective In this study, we compared the prostate health index (PHI) and the Prostate Imaging Reporting and Data System (PI‐RADS) before prostate biopsy and evaluated the utility of combining them in the diagnosis of prostate cancer (PC). Methods Between November 2021 and March 2023, 105 patients admitted to Gunma University Hospital for prostate biopsy after undergoing both MRI and PHI measurements were enrolled in this study. We investigated the diagnostic impacts of [−2]proPSA related indexes on clinically significant PC (csPC) and the complementary effects of PHI and PI‐RADS. Results The median of PHI was 59.9, and 72 patients (69%) were diagnosed with PC. The receiver operating characteristic (ROC) curve for patients diagnosed with PC indicated an area under the curve (AUC) of 0.816 for PHI and 0.753 for PI‐RADS. For PHI, when the sensitivity was 90% and 95%, the specificity was 51.5% and 45.5%, respectively. Both are higher than those of the conventional PSA‐related indices. In addition, the ROC curve in patients with a diagnosis of csPC ( n = 67) indicated an AUC of 0.793 for PHI and 0.746 for PI‐RADS. Furthermore, if biopsy was restricted to patients with PI‐RADS ≥ 4 or PHI ≥ 38.1, 21% of unnecessary biopsies could be avoided, with only one (1.5%) patient with csPC being missed. Conclusions PHI is more available for detecting csPC than PSA and PSA F/T. Moreover, there is a possibility that unnecessary prostate biopsies can be avoided by combining PHI and PI‐RADS.

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Yoshitaka Sekine

Gunma University

JAPAN
View details

Kazuhiro Suzuki

-

JAPAN
View details

Seiji Arai

Gunma University

JAPAN
View details